950 — Lees Pharmaceutical Holdings Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Annual income statement for Lees Pharmaceutical Holdings, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	HKAS	HKAS	HKAS	HKAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,266	1,233	1,053	1,400	1,436
Cost of Revenue
Gross Profit	806	771	551	753	730
Selling / General / Administrative Expenses
Research And Development
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	-712	1,157	1,009	1,287	1,350
Operating Profit	1,979	76.6	43.6	113	86
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,969	67.9	30.8	98.1	72.9
Provision for Income Taxes
Net Income After Taxes	1,960	45.8	19.9	68.6	50.6
Minority Interest
Net Income Before Extraordinary Items
Net Income	1,987	51.3	16.7	93.1	91.9
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,987	51.3	16.7	93.1	91.9
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.07	0.09	0.019	0.177	0.176
Dividends per Share